OCT 1 3 2000

K002871

D. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

[in Accordance with SMDA of 1990]

Page 1 of 1

YASARGIL ANEURYSM CLIPS

September 13, 2000

COMPANY:

Aesculap[®], Inc.

3773 Executive Center Parkway

Center Valley, PA 18034

CONTACT:

Joyce Thomas, Director Regulatory Affairs & Quality Assurance

610/231-0228 (phone)

610/231-3713 (fax)

TRADE NAME:

Yasargil Aneurysm Clips

COMMON NAME: Aneurysm Clips

DEVICE CLASS:

Class II

PRODUCT CODE: 84 HCH

CLASSIFICATION: 21 CFR Section 882.5200 - Clip, Aneurysm

REVIEW PANEL: Neurology

Division of General, Restorative, and Neurological Devices

DEVICE DESCRIPTION

The new Yasargil aneurysm clip patterns presented in this submission are designed to permanently or temporarily occlude cerebral aneurysms and are composed of either titanium alloy (Ti6AL4V) according to ISO 5832/3 or phynox (cobalt alloy) according to ISO 5832/7.

INDICATIONS FOR USE

The Yasargil Aneurysm Clips are intended for occlusion of cerebral aneurysms in either a temporary or permanent manner. They are applied with Aesculap clip appliers, which contain titanium alloy or phynox jaws.

PERFORMANCE DATA

No applicable performance standards have been promulgated under Section 514 of the Food, Drug and Cosmetic Act for this device system. Aesculap's Yasarqil Aneurysm Clips, however, are manufactured and labeled according to applicable ASTM and ISO Standards.

SUBSTANTIAL EQUIVALENCE

The new aneurysm clips described in this premarket notification are substantially equivalent to those in Aesculap's current Yasargil Titanium and Phynox Aneurysm Clip lines (K983758, K970050, K922272, K913765, K833652, K833650) with regard to intended use, fundamental scientific technology, design, and material.



OCT 1 3 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Joyce Thomas
Director, Regulatory Affairs and
Quality Assurance
Aesculap, Inc.
3773 Executive Center Parkway
Center Valley, Pennsylvania 18034

Re:

K002871

Trade Name: Yasargil Aneurysm Clips

Regulatory Class: II Product Code: HCH

Dated: September 13, 2000 Received: September 14, 2000

Dear Ms. Thomas:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

B. INDICATIONS FOR USE STATEMENT

Page 1 of 1

510(k) Number (i	f known):	K002871			
Device Name:	Yasar	rgil Aneurysm C	lips		
Indication for Us	se:				
The Yasargil Ane either a temporar appliers, which co	ry or permanen	it manner. They	are applied v	bral aneurys vith Aescula	ms in p clip
		-			
			•		
(PLEASE DO NOT W				PAGE IF NEED	DED)
Concurrence of CDF	RH, Office of De	evice Evaluation (ODE)		
	1				
	Mar	melljuga			
	(Division Sign-Off	f) al Restorative Devices			
	510(k) Number	K002871			-
Prescription Use	×	or Over-the-	Counter Use		<u>-</u>
(per 21 CFR 801.109)				Optional Format	2 10 00\
			(Optional Format	3-10-50)

K002871